AvailableView product →Experimental peptide
$40.00
Retatrutide (LY3437943) is a single, modified peptide under clinical development by Eli Lilly. It activates the GIP, GLP-1, and glucagon receptors and is not FDA approved. This 10 mg listing is presented strictly for laboratory research use.
A long-acting triple hormone-receptor agonist with activity at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Phase 3 clinical development is ongoing; this record does not represent an approved or commercially available drug product.
Scientific record reviewed 2026-07-13.
Product totals are confirmed now; shipping and applicable tax are shown before payment.
Review shipping policy ↗